Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Estrogen metabolites in a small cohort of patients with idiopathic pulmonary arterial hypertension.

Denver N, Homer NZM, Andrew R, Harvey KY, Morrell N, Austin ED, MacLean MR.

Pulm Circ. 2020 Mar 13;10(1):2045894020908783. doi: 10.1177/2045894020908783. eCollection 2020 Jan-Mar.

2.

Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen-hypoxia rat model by cardiac magnetic resonance imaging.

Jayasekera G, Wilson KS, Buist H, Woodward R, Uckan A, Hughes C, Nilsen M, Church AC, Johnson MK, Gallagher L, Mullin J, MacLean MR, Holmes WM, Peacock AJ, Welsh DJ.

Pulm Circ. 2020 Feb 10;10(1):2045894019897513. doi: 10.1177/2045894019897513. eCollection 2020 Jan-Mar.

3.

Notch3 signalling and vascular remodelling in pulmonary arterial hypertension.

Morris HE, Neves KB, Montezano AC, MacLean MR, Touyz RM.

Clin Sci (Lond). 2019 Dec 20;133(24):2481-2498. doi: 10.1042/CS20190835.

4.

Data for analysis of catechol estrogen metabolites in human plasma by liquid chromatography tandem mass spectrometry.

Denver N, Khan S, Stasinopoulos I, Church C, Homer NZM, MacLean MR, Andrew R.

Data Brief. 2019 Mar 8;23:103740. doi: 10.1016/j.dib.2019.103740. eCollection 2019 Apr.

5.

Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.

Kawut SM, Pinder D, Al-Naamani N, McCormick A, Palevsky HI, Fritz J, Smith KA, Mazurek JA, Doyle MF, MacLean MR, DeMichele A, Mankoff DA.

Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: 10.1513/AnnalsATS.201904-328RL. No abstract available.

PMID:
31314997
6.

Current strategies for quantification of estrogens in clinical research.

Denver N, Khan S, Homer NZM, MacLean MR, Andrew R.

J Steroid Biochem Mol Biol. 2019 Sep;192:105373. doi: 10.1016/j.jsbmb.2019.04.022. Epub 2019 May 18. Review.

7.

Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension.

Mair KM, Harvey KY, Henry AD, Hillyard DZ, Nilsen M, MacLean MR.

Eur Respir J. 2019 Jun 13;53(6). pii: 1801524. doi: 10.1183/13993003.01524-2018. Print 2019 Jun.

8.

Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-α.

Docherty CK, Nilsen M, MacLean MR.

J Am Heart Assoc. 2019 Mar 5;8(5):e011628. doi: 10.1161/JAHA.118.011628.

9.

Derivatization enhances analysis of estrogens and their bioactive metabolites in human plasma by liquid chromatography tandem mass spectrometry.

Denver N, Khan S, Stasinopoulos I, Church C, Homer NZ, MacLean MR, Andrew R.

Anal Chim Acta. 2019 Apr 25;1054:84-94. doi: 10.1016/j.aca.2018.12.023. Epub 2018 Dec 21.

10.

Negative experiences of pain and withdrawal create barriers to abscess care for people who inject heroin. A mixed methods analysis.

Summers PJ, Hellman JL, MacLean MR, Rees VW, Wilkes MS.

Drug Alcohol Depend. 2018 Sep 1;190:200-208. doi: 10.1016/j.drugalcdep.2018.06.010. Epub 2018 Jul 19.

PMID:
30055424
11.

The Role of Sex in the Pathophysiology of Pulmonary Hypertension.

Docherty CK, Harvey KY, Mair KM, Griffin S, Denver N, MacLean MR.

Adv Exp Med Biol. 2018;1065:511-528. doi: 10.1007/978-3-319-77932-4_31. Review.

PMID:
30051404
12.

Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension.

Dean A, Gregorc T, Docherty CK, Harvey KY, Nilsen M, Morrell NW, MacLean MR.

Am J Respir Cell Mol Biol. 2018 Mar;58(3):320-330. doi: 10.1165/rcmb.2017-0260OC.

13.

Serotonin Signaling Through the 5-HT1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension.

Hood KY, Mair KM, Harvey AP, Montezano AC, Touyz RM, MacLean MR.

Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1361-1370. doi: 10.1161/ATVBAHA.116.308929. Epub 2017 May 4.

14.

Klotho and Pulmonary Hypertension: Spinning a Yarn or the Thread of Life?

MacLean MR.

Hypertension. 2016 Nov;68(5):1106-1107. Epub 2016 Sep 26. No abstract available.

PMID:
27672024
15.

Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Mediated Redox Signaling and Vascular Remodeling by 16α-Hydroxyestrone in Human Pulmonary Artery Cells: Implications in Pulmonary Arterial Hypertension.

Hood KY, Montezano AC, Harvey AP, Nilsen M, MacLean MR, Touyz RM.

Hypertension. 2016 Sep;68(3):796-808. doi: 10.1161/HYPERTENSIONAHA.116.07668. Epub 2016 Jul 11.

16.

Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition.

Dean A, Nilsen M, Loughlin L, Salt IP, MacLean MR.

Hypertension. 2016 Aug;68(2):446-54. doi: 10.1161/HYPERTENSIONAHA.116.07353. Epub 2016 Jun 13.

17.

Regulation and function of miR-214 in pulmonary arterial hypertension.

Stevens HC, Deng L, Grant JS, Pinel K, Thomas M, Morrell NW, MacLean MR, Baker AH, Denby L.

Pulm Circ. 2016 Mar;6(1):109-17. doi: 10.1086/685079.

18.

The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1.

Johansen AK, Dean A, Morecroft I, Hood K, Nilsen M, Loughlin L, Anagnostopoulou A, Touyz RM, White K, MacLean MR.

Pulm Circ. 2016 Mar;6(1):82-92. doi: 10.1086/685023.

19.

Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, Preston IR, MacLean MR, Lahm T.

Pulm Circ. 2015 Sep;5(3):435-65. doi: 10.1086/682230.

20.

MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.

Deng L, Blanco FJ, Stevens H, Lu R, Caudrillier A, McBride M, McClure JD, Grant J, Thomas M, Frid M, Stenmark K, White K, Seto AG, Morrell NW, Bradshaw AC, MacLean MR, Baker AH.

Circ Res. 2015 Oct 23;117(10):870-883. doi: 10.1161/CIRCRESAHA.115.306806. Epub 2015 Aug 26. Erratum in: Circ Res. 2017 Feb 17;120(4):e6.

21.

A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension.

Wallace E, Morrell NW, Yang XD, Long L, Stevens H, Nilsen M, Loughlin L, Mair KM, Baker AH, MacLean MR.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1432-42. doi: 10.1164/rccm.201412-2148OC.

22.

Oestrogen receptor alpha in pulmonary hypertension.

Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, Maclean MR.

Cardiovasc Res. 2015 May 1;106(2):206-16. doi: 10.1093/cvr/cvv106. Epub 2015 Mar 12.

23.

Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.

Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, Docherty CK, Morrell NW, MacLean MR.

Am J Respir Crit Care Med. 2015 Mar 15;191(6):693-703. doi: 10.1164/rccm.201410-1802OC.

24.

Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension.

Grant JS, Morecroft I, Dempsie Y, van Rooij E, MacLean MR, Baker AH.

Pulm Circ. 2013 Dec;3(4):840-50. doi: 10.1086/674751.

25.

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, MacLean MR.

Am J Respir Crit Care Med. 2014 Aug 15;190(4):456-67. doi: 10.1164/rccm.201403-0483OC.

26.

Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis.

White K, Dempsie Y, Caruso P, Wallace E, McDonald RA, Stevens H, Hatley ME, Van Rooij E, Morrell NW, MacLean MR, Baker AH.

Hypertension. 2014 Jul;64(1):185-94. doi: 10.1161/HYPERTENSIONAHA.113.03037. Epub 2014 Apr 14.

PMID:
24732886
27.

Gender, sex hormones and pulmonary hypertension.

Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, Oka M.

Pulm Circ. 2013 Apr;3(2):294-314. doi: 10.4103/2045-8932.114756. Review.

28.

The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.

von Gise A, Archer SL, Maclean MR, Hansmann G.

Pulm Circ. 2013 Apr;3(2):275-7. doi: 10.4103/2045-8932.114751. No abstract available.

29.

Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR.

Br J Pharmacol. 2014 Feb;171(3):567-79. doi: 10.1111/bph.12281. Review.

30.

MicroRNAs in pulmonary arterial remodeling.

Grant JS, White K, MacLean MR, Baker AH.

Cell Mol Life Sci. 2013 Dec;70(23):4479-94. doi: 10.1007/s00018-013-1382-5. Epub 2013 Jun 6. Review.

31.

The influence of gender on the development of pulmonary arterial hypertension.

Dempsie Y, MacLean MR.

Exp Physiol. 2013 Aug;98(8):1257-61. doi: 10.1113/expphysiol.2012.069120. Epub 2013 Apr 26. Review.

32.

Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.

Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M, Loughlin L, Mair KM, MacLean MR.

Cardiovasc Res. 2013 Jul 1;99(1):24-34. doi: 10.1093/cvr/cvt064. Epub 2013 Mar 20.

33.

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, Jones P, Fox R, Clay I, Bonneau O, Konstantinova I, Pearce A, Rowlands DJ, Jarai G, Westwick J, MacLean MR, Thomas M.

Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89. doi: 10.1164/rccm.201206-1028OC. Epub 2012 Oct 18.

PMID:
23087024
34.

Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR.

Circulation. 2012 Aug 28;126(9):1087-98. doi: 10.1161/CIRCULATIONAHA.111.062927. Epub 2012 Aug 2.

PMID:
22859684
35.

A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, Upton P, Xin M, van Rooij E, Olson EN, Morrell NW, MacLean MR, Baker AH.

Circ Res. 2012 Jul 20;111(3):290-300. doi: 10.1161/CIRCRESAHA.112.267591. Epub 2012 Jun 19.

PMID:
22715469
36.

Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery.

Baranowska-Kuczko M, MacLean MR, Kozłowska H, Malinowska B.

Pharmacol Res. 2012 Sep;66(3):251-9. doi: 10.1016/j.phrs.2012.05.004. Epub 2012 May 22.

PMID:
22627170
37.

Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.

Morecroft I, White K, Caruso P, Nilsen M, Loughlin L, Alba R, Reynolds PN, Danilov SM, Baker AH, Maclean MR.

Mol Ther. 2012 Aug;20(8):1516-28. doi: 10.1038/mt.2012.70. Epub 2012 Apr 24.

38.

Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, Rabinovitch M, Maclean MR.

Respir Res. 2011 Dec 20;12:159. doi: 10.1186/1465-9921-12-159.

39.

MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling.

McDonald RA, Hata A, MacLean MR, Morrell NW, Baker AH.

Cardiovasc Res. 2012 Mar 15;93(4):594-604. doi: 10.1093/cvr/cvr299. Epub 2011 Nov 7. Review.

40.

Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.

Murray F, Maclean MR, Insel PA.

Handb Exp Pharmacol. 2011;(204):279-305. doi: 10.1007/978-3-642-17969-3_12. Review.

PMID:
21695645
41.

Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension.

Morecroft I, Doyle B, Nilsen M, Kolch W, Mair K, Maclean MR.

Br J Pharmacol. 2011 Jul;163(5):948-63. doi: 10.1111/j.1476-5381.2011.01305.x. Retraction in: Br J Pharmacol. 2017 May;174(9):911.

42.

Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.

White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, Baker AH, MacLean MR.

Physiol Genomics. 2011 Apr 27;43(8):417-37. doi: 10.1152/physiolgenomics.00249.2010. Epub 2011 Feb 8.

43.

The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension.

White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR.

Cardiovasc Res. 2011 May 1;90(2):373-82. doi: 10.1093/cvr/cvq408. Epub 2010 Dec 22.

PMID:
21177701
44.

The serotonin hypothesis of pulmonary hypertension revisited.

Maclean MR, Dempsie Y.

Adv Exp Med Biol. 2010;661:309-22. doi: 10.1007/978-1-60761-500-2_20. Review.

PMID:
20204739
45.

Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.

Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson R, Denby L, Dempsie Y, Long L, Morrell NW, Baker AH.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):716-23. doi: 10.1161/ATVBAHA.109.202028. Epub 2010 Jan 28.

PMID:
20110569
46.

In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension.

Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y, Millet C, MacLean MR.

Cardiovasc Res. 2010 Feb 1;85(3):593-603. doi: 10.1093/cvr/cvp306. Epub 2009 Sep 7.

PMID:
19736308
47.

Endothelial ET(B) limits vascular remodelling and development of pulmonary hypertension during hypoxia.

Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan FH, Dempsie Y, Nilsen M, Yanagisawa M, Maclean MR, Kotelevtsev YV, Webb DJ.

J Vasc Res. 2010;47(1):16-22. doi: 10.1159/000231717. Epub 2009 Aug 6.

48.

Cellular and molecular basis of pulmonary arterial hypertension.

Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-31. doi: 10.1016/j.jacc.2009.04.018. Review.

49.

Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension.

Morecroft I, Murray A, Nilsen M, Gurney AM, MacLean MR.

Br J Pharmacol. 2009 Aug;157(7):1241-9. doi: 10.1111/j.1476-5381.2009.00283.x. Epub 2009 Jun 5.

50.

Serotonin and pulmonary hypertension--from bench to bedside?

MacLean MR, Dempsie Y.

Curr Opin Pharmacol. 2009 Jun;9(3):281-6. doi: 10.1016/j.coph.2009.02.005. Epub 2009 Mar 13. Review.

PMID:
19286424

Supplemental Content

Loading ...
Support Center